GLOW blend dosage: reported doses and schedule
An unapproved skin-and-recovery blend with no human combination study found.
Also called: GLOW stack, GHK-Cu/BPC/TB blend.
Community blends · Unapproved three-ingredient peptide and copper mixture; ratios vary.
Typical reported dose: 2 mg GHK-Cu plus 0.4 mg each of BPC-157 and TB-500 once a day
- Daily reports, measured by GHK-Cu: 2.8 mg total: GHK-Cu 2 mg + BPC-157 0.4 mg + TB-500 0.4 mg daily. once daily, under the skin. Reported by users, occasional report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
- A lower-dose 50:10:10 plan: About 2.33 mg total: GHK-Cu 1.67 mg + BPC-157 0.333 mg + TB-500 0.333 mg daily. once daily, under the skin. Reported by users, rare report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
- Muscle-injection report, 40:10:10: 5 mg total daily from a GHK-Cu:BPC:TB ratio of 40:10:10. once daily, into muscle. Reported by users, rare report. Studied in: Adults discussing self-use; products and outcomes unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to GLOW blend (GHK-Cu + BPC-157 + TB-500)
- KLOW blend: GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
- Wolverine stack (BPC-157 + TB-500): An unapproved recovery blend with no controlled human trial of the premixed product.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- KPV: An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.